Saxenda generic
Saxenda is an anti-obesity drug owned by Novo Nordisk. Its active ingredient is Liraglutide, a GLP-1 receptor agonist. The drug was authorized for market use on December 23, 2014. It has a total of 44 drug patents, with 10 already expired. The most prominent dosage form of Saxenda is a subcutaneous solution.
When will Saxenda generic be available?
Based on the expiration of the Saxenda's last patent, the earliest possible date for the release of Saxenda generics is July 9, 2037. This is due to the patent US9968659 that covers the use of Liraglutide in cardiovascular conditions expiring on the said date.
Saxenda uses
Saxenda is primarily used for weight management and treating obesity. It is also utilized in a cardiovascular outcomes trial involving patients with type 2 diabetes and cardiovascular disease. Liraglutide, its active ingredient, is a GLP-1 receptor agonist. It works by helping to regulate the blood sugar levels and slows down gastric emptying.
Saxenda patent expiration
Saxenda has a vast patent portfolio with a total of 44 patents. The majority of these patents are related to automatic injection devices, formulations, and dosage mechanisms. The last patent due to expire is US9968659, titled 'Liraglutide in cardiovascular conditions', which extends the exclusivity of Saxenda until July 9, 2037. Below are the details of the patents: